Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 31, 2017

View Archived Issues

First subject dosed in phase I study of ORIC-101

National Cancer Center Japan and BrightPath collaborate on personalized cancer neoantigen vaccine

Novel leukotriene A-4 hydrolase inhibitors identified at Novartis

The University of Michigan discloses new proteolysis targeting chimera compounds

New dopamine D1 receptor positive allosteric modulators divulged by UCB

Tazemetostat generally well tolerated and has antitumor activity in pediatric patients

Baylor College of Medicine describes novel Steroid receptor coactivator regulators

AbbVie identifies new lysophosphatidic acid receptor 1 antagonists

STNM-01 reverses tissue remodeling in patients with ulcerative colitis

Preliminary safety data from a phase II study of fruquintinib plus gefitinib in EGFR-mutant NSCLC

Merrimack Pharmaceuticals' MM-121 granted FDA orphan status for heregulin-positive NSCLC

Patient enrollment ongoing in phase I/II trial of rAAV9.CMV.hNAGLU for the treatment of MPSIIIB

Pegfilgrastim biosimilar from Sandoz accepted for EMA review

New lower dose of rivaroxaban approved by FDA

Erlotinib plus onalespib demonstrates disease control in phase I study in EGFR-mutant NSCLC

Norovirus tablet vaccine VXA-G1.1-NN immunogenic in phase I study

Rolling NDA submitted for Epidiolex for Lennox-Gastaut syndrome and Dravet syndrome

Amgen reviews pipeline progress for third quarter 2017

First patient enrolled in phase III trial of piclidenoson in rheumatoid arthritis

Daiichi Sankyo reports phase III data on pexidartinib in tenosynovial giant cell tumor

Mersana Therapeutics' antibody-drug conjugate XMT-1536 moves into clinical development

Novartis submits sBLA for Kymriah for relapsed or refractory DLBCL

Aviragen Therapeutics and Vaxart announce merger

Kymera Therapeutics announces Series A financing round

Novel anticancer candidate ABC-131 shows advantages over established antimicrotubule drugs

Fruquintinib begins new Chinese phase III trial in advanced gastric cancer

Xynomic Pharma acquires rights to RAF inhibitor BI-882370 from Boehringer Ingelheim

Sumitomo Dainippon updates milestones of second quarter of fiscal 2017

Voyager Therapeutics regains worldwide rights to VY-AADC program for advanced Parkinson's disease

ReNeuron offers update from phase II study of CTX cell therapy candidate for stroke disability

Alkermes plans phase III trial of aripiprazole formulation in schizophrenia

Amgen and Kirin agree that Kirin-Amgen joint venture will become wholly owned subsidiary of Amgen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...